Utpalendu Paul

Utpalendu Paul

Auto-generated profile, based on publicly available information

Utpalendu Paul

Department of Biotechnology, School of Bio Science and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Sanjeeva SrivastavaSanjeeva Srivastava
Sanjeeva Srivastava
SAShalini Aggarwal
Shalini Aggarwal
AKAmit Karmakar
Amit Karmakar
SKSanjana Krishnakumar
Sanjana Krishnakumar
UPUtpalendu Paul
Utpalendu Paul
GBGraham Roy Ball
Graham Roy Ball
Malaria is one of the neglected infectious diseases, and drugs are the first line of action taken against the onset of malaria as therapeutics. The drugs can be of either natural or artificial origin. Drug development has multiple impediments grouped under three categories, a. drug discovery and screening, b. the drug's action on the host and the pathogen, and c. clinical trials. Drug development takes coon’s age from discovery to the market after FDA approval. At the same time, targeted organisms develop drug resistance quicker than drug approval, raising the requirement for advancement in drug development. The approach to explore drug candidates using the classical methods from natural sources, computation-based docking, mathematical and machine learningbased high throughput in silico models or drug repurposing has been investigated and developed. Also, drug development with information about the interaction between Plasmodium species and its host, humans, may facilitate obtaining an efficient drug cohort for further drug discovery or repurposing expedition. However, drugs may have side effects on the host system. Hence, machine learning and systems-based approaches may provide a holistic view of genomic, proteomic, and transcriptomic data and their interaction with the selected drug candidates. This review comprehensively describes the drug discovery workflows using drug and target screening methodologies, followed by possible ways to check the binding affinity of the drug and targets using various docking software.

4 November 2022
Verified
Book Chapter
Open access
DADivya Aggarwal
Divya Aggarwal
NANisha Arunachalam
Nisha Arunachalam
AAAsha Ashok
Asha Ashok
SBSudeshna Bagchi
Sudeshna Bagchi
SBSubhadeep Banerjee
Subhadeep Banerjee
HZHaotian Zheng
Haotian Zheng